


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on December 22, 2006.



Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. SER-100X
Serial No. 10/553,430

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christopher Hug, Harvey F. Lodish
Serial No. : 10/553,430
Filed : October 18, 2005
Conf. No. : 3770
For : Use of T-Cadherin as a Target

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted copies of the U.S. patents cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Published International Application WO 99/19477, cited as F2 on the attached form PTO/SB/08, is written in a foreign language. In accordance with MPEP §609A(3), Applicants are submitting herewith a copy of the International Search Report from corresponding International Application No. PCT/US2004/040363 which was filed on December 2, 2004. Applicants have also

included U.S. Patent No. 6,809,175, cited as U2, on attached form PTO/SB/08. The U.S. patent is cited on the International Search Report as a patent family member of WO 99/19477 and is believed to be an English language equivalent of WO 99/19477. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of references cited therein; copy of International Search Report.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/553,430	
			Filing Date	October 18, 2005	
			First Named Inventor	Christopher Hug	
			Art Unit		
			Examiner Name		
Sheet	1	of	8	Attorney Docket Number	SER-100X

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-6,358,920 B1	03-19-2002	Blaschuk <i>et al.</i>	All
	U2	US-6,809,175 B1	10-26-2004	Forssmann <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 02/053726 A2	07-11-2002	HybriGenics <i>et al.</i>	All	
	F2	WO 99/19477 A1	04-22-1999	Forssmann	All	X
	F3	WO 2004/096272 A2	11-11-2004	Cytos Biotechnology	All	
	F4	WO 2005/049861 A2	06-02-2005	Epigenomics AG	All	
	F5	WO 02/23184 A1	03-21-2002	Eleanor Roosevelt Institute <i>et al.</i>	All	
	F6	WO 01/60853 A1	08-23-2001	Pharmacia AB	All	
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/553,430	
			Filing Date	October 18, 2005	
			First Named Inventor	Christopher Hug	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	8	Attorney Docket Number	SER-100X

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R1	ARITA, Y. <i>et al.</i> "Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity", <i>Biochem Biophys Res Commun</i> , 1999, pp. 79-83, Vol. 257, No. 1.		
	R2	BERG, A.H. <i>et al.</i> "The adipocyte-secreted protein Acrp30 enhances hepatic insulin action", <i>Nature Medicine</i> , August 2001, pp. 947-953, Vol. 7, No. 8.		
	R3	BODYAK, N. <i>et al.</i> "Gene expression profiling of the aging mouse cardiac myocytes", <i>Nucleic Acids Research</i> , 2002, pp. 3788-3794, Vol. 30, No. 17.		
	R4	BOGAN, J.S. <i>et al.</i> "Insulin-Responsive Compartments Containing GLUT4 in 3T3-L1 and CHO Cells: Regulation by Amino Acid Concentrations", <i>Mol Cell Biol</i> , July 2001, pp. 4785-4806, Vol. 21, No. 14.		
	R5	BRONIKOWSKI, A.M. <i>et al.</i> "Lifelong voluntary exercise in the mouse prevents age-related alterations in gene expression in the heart", <i>Physiol Genomics</i> , 2003, pp. 129-138, Vol. 12.		
	R6	CASTLE, C.K. <i>et al.</i> "Lipoprotein Profile Characterization of the KKA ^Y Mouse, a Rodent Model of Type II Diabetes, Before and After Treatment With the Insulin-Sensitizing Agent Pioglitazone", <i>Arterioscler Thromb</i> , 1993, pp. 302-309, Vol. 13, No. 2.		
	R7	CHEBATH, J. <i>et al.</i> "Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities", <i>Eur Cytokine Netw</i> , December 1997, pp. 359-365, Vol. 8, No. 4.		
	R8	CONACCI-SORRELL, M. <i>et al.</i> "The cadherin-catenin adhesion system in signaling and cancer", <i>J Clin Invest</i> , April 2002, pp. 987-991, Vol. 109, No. 8.		
	R9	DOYLE, D.D. <i>et al.</i> "T-cadherin Is a Major Glycophosphoinositol-anchored Protein Associated with Noncaveolar Detergent-insoluble Domains of the Cardiac Sarcolemma", <i>J Biol Chem</i> , March 20, 1998, pp. 6937-43, Vol. 273, No. 12.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/553,430	
			Filing Date	October 18, 2005	
			First Named Inventor	Christopher Hug	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	8	Attorney Docket Number	SER-100X

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R10	EDWARDS, P.R. and R. Leatherbarrow. "Determination of Association Rate Constants by an Optical Biosensor Using Initial Rate Analysis", <i>Anal Biochem</i> , 1997, pp. 1-6, Vol. 246, No. 1.		
	R11	ELBASHIR, S.M. <i>et al.</i> "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", <i>Nature</i> , May 24, 2001, pp. 494-498, Vol. 411, No. 6836.		
	R12	ELLINGTON, A.R. and J. Szostak. " <i>In vitro</i> selection of RNA molecules that bind specific ligands", <i>Nature</i> , August 30, 1990, pp. 818-822, Vol. 346, No. 6287.		
	R13	ELLIOT, J.L. and A. Pestronk. "Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin", <i>Neurology</i> , May 1994, pp. 967-968, Vol. 44, No. 5.		
	R14	FEBBRAIO, M.A. and B.K. Pedersen. "Muscle-derived interleukin-6: mechanisms for activation and possible biological roles", <i>FASEB</i> , September 2002, pp. 1335-1347, Vol. 16, No. 11.		
	R15	FEINGLOS, M.N. <i>et al.</i> "Modification of Postprandial Hyperglycemia With Insulin Lispro Improves Glucose Control in Patients With Type 2 Diabetes", <i>Diabetes Care</i> , October 1997, pp. 1539-1542, Vol. 20, No. 10.		
	R16	FIELDS, S. and O.-K. Song. "A novel genetic system to detect protein-protein interactions", <i>Nature</i> , July 20, 1989, pp. 245-246, Vol. 340.		
	R17	FROMONT-RACINE, M. <i>et al.</i> "Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens", <i>Nat Genet</i> , July 16, 1997, pp. 277-282, Vol. 16, No. 3.		
	R18	FRUEBIS, J. <i>et al.</i> "Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice", <i>Proc Natl Acad Sci USA</i> , February 13, 2001, pp. 2005-2010, Vol. 98, No. 4.		
	R19	GRANTHAM, R. "Amino Acid Difference Formula to Help Explain Protein Evolution", <i>Science</i> , 1974, pp. 862-864, Vol. 185, No. 4154.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/553,430	
			Filing Date	October 18, 2005	
			First Named Inventor	Christopher Hug	
			Group Art Unit		
			Examiner Name		
Sheet	4	of	8	Attorney Docket Number	SER-100X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R20	HARA, K. <i>et al.</i> "Genetic Variation in the Gene Encoding Adiponectin Is Associated With an Increased Risk of Type 2 Diabetes in the Japanese Population", <i>Diabetes</i> , February 2002, pp. 536-540, Vol. 51, No. 2.	
	R21	HOLMAN, R.R. <i>et al.</i> "A Randomized Double-Blind Trial of Acarbose in Type 2 Diabetes Shows Improved Glycemic Control Over 3 Years (U.K. Prospective Diabetes Study 44)", <i>Diabetes Care</i> , June 1999, pp. 960-964, Vol. 22, No. 6.	
	R22	HU, E. <i>et al.</i> "AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity", <i>J Biol Chem</i> , May 3, 1996, pp. 10697-10703, Vol. 271, No. 18.	
	R23	HUANG, Z. <i>et al.</i> "T-Cadherin-Mediated Cell Growth Regulation Involves G ₂ Phase Arrest and Requires p21 ^{CIP1/WAF1} Expression", <i>Mol Cell Biol</i> , January 2003, pp. 566-578, Vol. 23, No. 2.	
	R24	IVANOV, D. <i>et al.</i> "Expression of cell adhesion molecule T-cadherin in the human vasculature", <i>Histochem Cell Biol</i> , 2001, pp. 231-242, Vol. 115, No. 3.	
	R25	KNIGHT, D.M. <i>et al.</i> "Construction and Initial Characterization of a Mouse-Human Chimeric Anti-TNF Antibody", <i>Mol Immunol</i> , 1993, pp. 1443-1453, Vol. 30, No. 16.	
	R26	KOLLET, O. <i>et al.</i> "The Soluble Interleukin-6 (IL-6) Receptor/IL-6 Fusion Protein Enhances In Vitro Maintenance and Proliferation of Human CD34 ⁺ CD38 ^{-low} Cells Capable of Repopulating Severe Combined Immunodeficiency Mice", <i>Blood</i> , August 1, 1999, pp. 923-931, Vol. 94, No. 3.	
	R27	KONDO, H. <i>et al.</i> "Association of Adiponectin Mutation With Type 2 Diabetes: A Candidate Gene for the Insulin Resistance Syndrome", <i>Diabetes</i> , July 2002, pp. 2325-2328, Vol. 51, No. 7.	
	R28	KOSMIDOU, I. <i>et al.</i> "Production of Interleukin-6 by Skeletal Myotubes: Role of Reactive Oxygen Species", <i>Am J Respir Cell Mol Biol</i> , 2002, pp. 587-593, Vol. 26, No. 5.	
	R29	LEE, C.K. "Gene Expression Profile of Aging and Its Retardation by Caloric Restriction", <i>Science</i> , August 27, 1999, pp. 1390-1393, Vol. 285.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/553,430	
			Filing Date	October 18, 2005	
			First Named Inventor	Christopher Hug	
			Group Art Unit		
			Examiner Name		
Sheet	5	of	8	Attorney Docket Number	SER-100X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R30	LINDSAY, R.S. <i>et al.</i> "Adiponectin and development of type 2 diabetes in the Pima Indian population", <i>Lancet</i> , July 6, 2002, pp. 57-58, Vol. 360, No. 9326.	
	R31	LIU, X. <i>et al.</i> "Generation of Mammalian Cells Stably Expressing Multiple Genes at Predetermined Levels", <i>Anal Biochem</i> , 2000, pp. 20-28, Vol. 280, No. 1.	
	R32	MAEDA, K. <i>et al.</i> "cDNA Cloning and Expression of a Novel Adipose Specific Collagen-like Factor, apM1 (Adipose Most Abundant Gene Transcript 1)", <i>Biochem Biophys Res Commun</i> , 1996, pp. 286-289, Vol. 221, No. 2.	
	R33	MAEDA, N. <i>et al.</i> "Diet-induced insulin resistance in mice lacking adiponectin/ACRP 30", <i>Nat Med</i> , July 2002, pp. 731-737, Vol. 8, No. 7.	
	R34	NAVIAUX, R.K. <i>et al.</i> "The pCL Vector System: Rapid Production of Helper-Free, High-Titer, Recombinant Retroviruses", <i>J Virol</i> , August 1996, pp. 5701-5705, Vol. 70, No. 8.	
	R35	NIERMANN, T. <i>et al.</i> "The Glycosyl Phosphatidylinositol Anchor of Human T-Cadherin Binds Lipoproteins", <i>Biochem Biophys Res Commun</i> , 2000, pp. 1240-1247, Vol. 276, No. 3.	
	R36	OGAWA, Y. <i>et al.</i> "Molecular Cloning of Rat Obese cDNA and Augmented Gene Expression in Genetically Obese Zucker Fatty (<i>fa/fa</i>) Rats", <i>J Clin Invest</i> , September 1995, pp. 1647-1652, Vol. 96, No. 3.	
	R37	OKAMOTO, Y. <i>et al.</i> "An Adipocyte-Derived Plasma Protein, Adiponectin, Adheres to Injured Vascular Walls", <i>Horm Metab Res</i> , 2000, pp. 47-50, Vol. 32, No. 2.	
	R38	PANIDIS, D. <i>et al.</i> "Serum adiponectin levels in women with polycystic ovary syndrome", <i>Hum Reprod</i> , 2003, pp. 1790-1796, Vol. 18, No. 9.	
	R39	PELLEYMOUNTER, M.A. <i>et al.</i> "Effects of the obese Gene Product on Body Weight Regulation in <i>ob/ob</i> Mice", <i>Science</i> , July 28, 1995, pp. 540-543, Vol. 269, No. 5223.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/553,430	
			Filing Date	October 18, 2005	
			First Named Inventor	Christopher Hug	
			Group Art Unit		
			Examiner Name		
Sheet	6	of	8	Attorney Docket Number	SER-100X

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R40	PETRIDOU, E. <i>et al.</i> "Plasma Adiponectin Concentrations in Relation to Endometrial Cancer: A Case-Control Study in Greece", <i>J Clin Endocrinol Metab</i> , 2003, pp. 993-997, Vol. 88, No. 3.		
	R41	PIERCY, V. <i>et al.</i> "Potential Benefit of Inhibitors of Advanced Glycation End Products in the Progression of Type II Diabetes: A Study With Aminoguanidine in C57/BLKsJ Diabetic Mice", <i>Metabolism</i> , December 1998, pp. 1477-1480, Vol. 47, No. 12.		
	R42	PIERCY, V. <i>et al.</i> "Acceleration of the Development of Diabetes in Obese Diabetic (db/db) Mice by Nicotinamide: A Comparison With Its Antidiabetic Effects in Non-Obese Diabetic Mice", <i>Metabolism</i> , December 2000, pp. 1548-1554, Vol. 49, No. 12.		
	R43	RAMSAY, J.E. <i>et al.</i> "Paradoxical Elevation in Adiponectin Concentrations in Women with Preeclampsia" <i>Hypertension</i> , 2003, pp. 891-894, Vol. 42, No. 5.		
	R44	RASMUSSEN, R.K. <i>et al.</i> "Two-dimensional electrophoretic analysis of human breast carcinoma proteins: Mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2", <i>Electrophoresis</i> , 1997, pp. 588-598, Vol. 18, Nos. 3-4.		
	R45	ROTH, J.L. <i>et al.</i> "The Metabolic Syndrome: Where Are We and Where Do We Go?", <i>Nut Rev</i> , October 2002, pp. 335-337, Vol. 60. No. 11.		
	R46	SCHERER, P.E. <i>et al.</i> "A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes", <i>J Biol Chem</i> , November 10, 1995, pp. 26746-26749, Vol. 270, No. 45.		
	R47	SCHINDLER, U. and V. Baichwal. "Three NF- κ B Binding Sites in the Human E-Selectin Gene Required for Maximal Tumor Necrosis Factor Alpha-Induced Expression", <i>Mol Cell Biol</i> , September 1994, pp. 5820-5831, Vol. 14, No. 9.		
	R48	TAKEUCHI, T. <i>et al.</i> "Expression of T-Cadherin (CDH13, H-Cadherin) in Human Brain and Its Characteristics as a Negative Growth Regulator of Epidermal Growth Factor in Neuroblastoma Cells", <i>J Neurochem</i> , 2000, pp. 1489-1497, Vol. 74, No. 4.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/553,430	
			Filing Date	October 18, 2005	
			First Named Inventor	Christopher Hug	
			Group Art Unit		
			Examiner Name		
Sheet	7	of	8	Attorney Docket Number	SER-100X

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R49	TANIHARA, H. <i>et al.</i> "Cloning of Five Human Cadherins Clarifies Characteristic Features of Cadherin Extracellular Domain and Provides Further Evidence for Two Structurally Different Types of Cadherin", <i>Cell Adhes Commun</i> , 1994, pp. 15-26, Vol. 2, No. 1.		
	R50	TKACHUK, V.A. <i>et al.</i> "Identification of an atypical lipoprotein-binding protein from human aortic smooth muscle as T-cadherin", <i>FEBS Lett</i> , 1998, pp. 208-212, Vol. 421, No. 3.		
	R51	TSAO, T.-S. <i>et al.</i> "Oligomerization State-dependent Activation of NF-κB Signaling Pathway by Adipocyte Complement-related Protein of 30 kDa (Acrp30)", <i>J Biol Chem</i> , August 16, 2002, pp. 29359-29362, Vol. 277, No. 33.		
	R52	TSAO, T.-S. <i>et al.</i> "Role of Disulfide Bonds in Acrp30/Adiponectin Structure and Signaling Specificity", <i>J Biol Chem</i> , December 12, 2003, pp. 50810-50817, Vol. 278, No. 50.		
	R53	UEDA, H. <i>et al.</i> "Age-dependent changes in phenotypes and candidate gene analysis in a polygenic animal model of Type II diabetes mellitus; NSY mouse", <i>Diabetologia</i> , 2000, pp. 932-938, Vol. 43, No. 7.		
	R54	WEINDRUCH, R. <i>et al.</i> "Gene expression profiling of aging using DNA microarrays", <i>Mech Ageing Dev</i> , 2002, pp. 177-193, Vol. 123, Nos. 2-3.		
	R55	WEINDRUCH, R. <i>et al.</i> "Microarray Profiling of Gene Expression in Aging and Its Alteration by Caloric Restriction in Mice", <i>J Nutr</i> , 2001, pp. 918S-923S, Vol. 131, No. 3.		
	R56	WELLE, S. <i>et al.</i> "Gene expression profile of aging in human muscle", <i>Physiol Genomics</i> , 2003, pp. 149-159, Vol. 14, No. 2.		
	R57	XU, A. <i>et al.</i> "The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice", <i>J Clin Invest</i> , July 2003, pp. 91-100, Vol. 112, No. 1.		
	R58	YAMAUCHI, T. <i>et al.</i> "Cloning of adiponectin receptors that mediate antidiabetic metabolic effects", <i>Nature</i> , June 12, 2003, pp. 762-769, Vol. 423, No. 6941.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/553,430	
			Filing Date	October 18, 2005	
			First Named Inventor	Christopher Hug	
			Group Art Unit		
Examiner Name					
Sheet	8	of	8	Attorney Docket Number	SER-100X

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R58	YAMAUCHI, T. <i>et al.</i> "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity", <i>Nat Med</i> , August 2001, pp. 941-946, Vol. 7, No. 8.		
	R60	YOKOTA, T. <i>et al.</i> "Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages", <i>Blood</i> , September 1, 2000, pp. 1723-1732, Vol. 96, No. 5.		
	R61	ZOCALI, C. <i>et al.</i> "Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors", <i>Kidney Int Suppl</i> , 2003, pp. S-98-S-102, Vol. 63, Sup. 84.		
	R62	ROBINSON, S.W. <i>et al.</i> "Genetic Models of Obesity and Energy Balance in the Mouse" <i>Annu. Rev. Genet.</i> , 2000, pp. 687-745, Vol. 34.		
	R63	TYRBERG, B. <i>et al.</i> "Diabetes development in T-cadherin deficient mice" <i>Database Biosis [Online] Biosciences Information Service</i> , August 2003, Database Accession No. PREV200300518094, XP008051535, Philadelphia, PA.		
	R64	HUG, C. <i>et al.</i> "T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin" <i>PNAS</i> , July 13, 2004, pp. 10308-10313, Vol. 101, No. 28.		
	R65			
	R66			
	R67			
	R68			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.